INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
Search

All disclosures

Every ingested record across SEC Form 4, 13F, House PTRs and Robinhood Chain, searchable by ticker, name or wallet address.

Results

Data sources
SEC Form 45h ago
House PTR5h ago
SEC 13F5h ago
Robinhood Chain5h ago

Results

82,076 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
9
DV
Dixon Jonathan V.GENERAL COUNSEL
BNGOBionano Genomics, Inc.
Grant or award
A—
26.1K sh
Feb 2, 2026Feb 4, 2026
Page 1617 of 2052
← PrevNext →
traded Feb 2, 2026
+2d
SEC Form 4

Evidence

9
KA
Kleczynski Robert ASVP, Controller & Tax
EXCEXELON CORP
Option exercise
M—
1,474 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
CJ
Conway Kevin JohnChief Financial Officer
GBIOGeneration Bio Co.
Option exercise
M—
235 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
SR
Shrewsbury RondaDirector
SRCE1ST SOURCE CORP
Grant or award
A$16K
243 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

9
JM
Jones Jeanne MEVP, CFO, Audit & Risk
EXCEXELON CORP
Grant or award
A—
18.8K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
GW
Go WilliamChief Medical Officer
JANXJanux Therapeutics, Inc.
Grant or award
A—
154.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
KA
Kleczynski Robert ASVP, Controller & Tax
EXCEXELON CORP
Option exercise
M—
1,684 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
KA
Kleczynski Robert ASVP, Controller & Tax
EXCEXELON CORP
Grant or award
A—
7,019 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

9
JM
Jones Jeanne MEVP, CFO, Audit & Risk
EXCEXELON CORP
Grant or award
A—
24.7K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

8
NA
Novack Jeffrey AdamSecretary and General Counsel
CDNACareDx, Inc.
Tax withholding
F$61K
2,970 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

8
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$8,830
200 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

8
GS
Gummadi SuryaPresident - Americas
CTSHCOGNIZANT TECHNOLOGY SOLUTIONS CORP
Open-market sale · 10b5-1 plan
SELL$144K
1,728 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

8
OO
Okupe OluyemiChief Financial Officer
HIMSHims & Hers Health, Inc.
Open-market sale · 10b5-1 plan
SELL$139K
5,262 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

8
NA
Novack Jeffrey AdamSecretary and General Counsel
CDNACareDx, Inc.
Tax withholding
F$51K
2,492 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

8
FJ
Fox-Geen JeremyChief Financial Officer
CRCLCircle Internet Group, Inc.
Tax withholding
F$248K
3,877 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

8
AJ
Allaire JeremyDirector, Chairman and CEO
CRCLCircle Internet Group, Inc.
Tax withholding
F$537K
8,404 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

6
AJ
Allaire JeremyDirector, Chairman and CEO
CRCLCircle Internet Group, Inc.
Option exercise
M—
2,434 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

6
FD
Feierstein Matthew DavidPresident
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$108K
10.0K sh
Feb 4, 2026Feb 4, 2026
traded Feb 4, 2026
+0dSEC Form 4

Evidence

6
FD
Feierstein Matthew DavidPresident
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$8,388
720 sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

6
RR
Remer Eric RichardDirector, Chief Executive Officer
EVCMEverCommerce Inc.
Open-market sale · 10b5-1 plan
SELL$159K
14.7K sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

5
ZN
Zojwalla NaseemCHIEF MEDICAL OFFICER
OLMAOlema Pharmaceuticals, Inc.
Grant or award
A—
250.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
RG
Russotti GregorySee Remarks
IPSCCentury Therapeutics, Inc.
Grant or award
A—
265.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
TA
Thompson Travis AlvinChief Financial Officer
BCYCBICYCLE THERAPEUTICS PLC
Grant or award
A—
58.0K sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

5
RS
Randhawa SimratEVP, Head of R&D
DNTHDianthus Therapeutics, Inc. /DE/
Grant or award
A—
150.0K sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

5
CC
Cowan ChadChief Scientific Officer
IPSCCentury Therapeutics, Inc.
Grant or award
A—
265.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
SR
Savitz RyanEVP, CFO & CBO
DNTHDianthus Therapeutics, Inc. /DE/
Grant or award
A—
150.0K sh
Feb 3, 2026Feb 4, 2026
traded Feb 3, 2026
+1dSEC Form 4

Evidence

5
CD
Carr DouglasSVP Finance & Operations
IPSCCentury Therapeutics, Inc.
Grant or award
A—
225.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
VV
Vultaggio VincentPAO and PFO
ZNTLZentalis Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL$6,477
2,540 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
PB
Pfeiffenberger BrentDirector, President and CEO
IPSCCentury Therapeutics, Inc.
Grant or award
A—
945.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
BD
Bharucha DavidChief Medical Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
204.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
CT
Chuang Patrick T.Senior VP, Memory Design
GSITGSI TECHNOLOGY INC
Grant or award
A—
20.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
NE
Nelson Jeffrey EdwardChief Operating Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
204.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
ZN
Zojwalla NaseemCHIEF MEDICAL OFFICER
OLMAOlema Pharmaceuticals, Inc.
Grant or award
A—
106.3K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
NE
Nelson Jeffrey EdwardChief Operating Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
136.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
BD
Bharucha DavidChief Medical Officer
MISTMilestone Pharmaceuticals Inc.
Grant or award
A—
136.0K sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
NP
Naude PierreDirector
NCNOnCino, Inc.
Grant or award
A—
3,516 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
SC
Saldanha CraigChief Product Officer
YELPYELP INC
Open-market sale · 10b5-1 plan
SELL$33K
1,200 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
NA
Novack Jeffrey AdamSecretary and General Counsel
CDNACareDx, Inc.
Grant or award
A—
4,342 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

5
HL
Heeson LeeEVP, Head of Incyte Intl
INCYINCYTE CORP
Tax withholding
F$11K
111 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence

3
BA
Bachrodt AmySVP, Finance
MAZEMaze Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$50K
4,844 sh
Feb 2, 2026Feb 4, 2026
traded Feb 2, 2026
+2dSEC Form 4

Evidence